NDA/BLA filedconf 0.75

reproxalap — NDA/BLA filed

$ALDX · Aldeyra Therapeutics, Inc. · dry eye disease

Event date

Date TBD

Sponsor runway

38 mo

$65.0M liquid

Evidence

“standardized treatment estimates and confidence intervals for the primary endpoints of all proposed commercial dosing regimen efficacy clinical trials of reproxalap submitted to the New Drug Application for the treatment of dry eye disease”

Source: 8-K filed 2026-05-01View on EDGAR ↗0001193125-26-199157

Comparable historical nda/bla fileds· last 5 years · same indication

Ticker	Drug	Date	Outcome
$ALDX	reproxalap	2025-07-17	unknown
$ALDX	reproxalap	2024-11-01	unknown
$ALDX	reproxalap	2023-02-07	unknown
$ALDX	reproxalap	2023-02-01	unknown

Recent insider activity· ±90 days

3 insiders · 2 buys · 0 sells

Grant

2026-03-27

Brady Todd C

President and CEO

1,880,510 @ ——

Grant

2026-03-27

Brady Todd C

President and CEO

632,318 @ ——

Buy

2026-03-19

DOUGLAS RICHARD

Director

70,000 @ $1.40$98K

Buy

2026-03-18

Alfieri Michael

Principal Financial Officer

5,000 @ $1.42$7K

Date	Insider	Action	Shares	Price	Value
2026-03-27	Brady Todd CPresident and CEO	Grant	1,880,510	—	—
2026-03-27	Brady Todd CPresident and CEO	Grant	632,318	—	—
2026-03-19	DOUGLAS RICHARDDirector	Buy	70,000	$1.40	$98K
2026-03-18	Alfieri MichaelPrincipal Financial Officer	Buy	5,000	$1.42	$7K

← All catalysts for $ALDX